Key Points {#FPar1}
==========

The Life Interference Questionnaire for Growth Hormone Deficiency (LIQ-GHD) is a newly developed questionnaire to evaluate the burden of growth hormone injections in children (and their caregivers) and adults.A robust scientific instrument development approach was followed, yielding a tool with evidence of score reliability and validity.Additional analysis and on-going use of this questionnaire in clinical trials is recommended.

Introduction {#Sec1}
============

The prevalence of pediatric growth hormone deficiency (GHD) is estimated at approximately 1:4000 to 1:10,000 \[[@CR1]--[@CR4]\]. The most apparent feature of GHD in children is growth failure or growth restriction. Metabolic consequences include impaired lipid metabolism, impaired protein synthesis, and impaired bone mineralization. GHD in children may also impact psychosocial development, resulting in poor self-image and social isolation. Short stature is also linked to a decrease in quality of life (QoL) \[[@CR5]--[@CR7]\].

Recombinant human growth hormone (r-hGH) replacement therapy has been available to safely and effectively treat adults and children with GHD for the last several decades to (i) increase height during childhood; (ii) attain adult height targets; (iii) minimize adverse events; (iv) achieve cost-effective treatment \[[@CR8]\]; and (v) improve QoL (since taller height in children is associated with a higher QoL) \[[@CR9]\].

Therapy with r-hGH involves administration of subcutaneous injections given daily over the long-term (e.g., ≥ 5 years), until final height has been attained. Given the duration of r-hGH treatment, patients often do not optimally comply with treatment \[[@CR10], [@CR11]\], and non-compliance has been shown to be the most common cause of reduced height velocity in children \[[@CR11]--[@CR13]\]. Studies have also demonstrated a reduction in adherence over time \[[@CR13]\].

There are many reasons for non-compliance, including complexity of regimen, difficulty in understanding potential treatment benefits, long-term treatment duration, perception of injections as painful, adolescence, and living in a busy, chaotic household \[[@CR14]--[@CR17]\]. However, the current literature suggests that little information exists describing the burden of administering daily growth hormone (GH) injections over the long-term. Further, there are currently no clinical outcome assessment (COA) measures available that can adequately assess the impacts and burden of r-hGH injections.

Since the administration of the injection to children often involves both the caregiver and patient, COA measures designed to evaluate r-hGH injection treatment burden should include feedback from both parties. A dyad approach to COA measurement (i.e., where the patient and caregiver read and answer questions together) may be useful to overcome concordance issues that arise in obtaining information from the caregiver or patient separately \[[@CR18]\]. Although little research has been conducted to evaluate dyad-administered COAs, a study by Ungar et al. \[[@CR19]\] suggested that a dyad approach could help children by enabling them to answer questionnaire items accurately, providing additional support in terms of comprehension or recall problems.

Thus, the overall goal of this research was to develop a new questionnaire, the Life Interference Questionnaire for Growth Hormone Deficiency (LIQ-GHD), to assess r-hGH injection treatment burden. The LIQ-GHD addresses an important measurement gap and offers versions for both adult and child--parent dyad administration.

The research summarizing the development and preliminary psychometric evaluation of the LIQ-GHD is presented here.

Objectives {#Sec2}
==========

The specific objectives of this research were to (i) establish evidence of content validity for the LIQ-GHD through qualitative research activities; and (ii) evaluate the hypothesized factor structure and preliminary score psychometric performance in a cross-sectional observational study.

Methods {#Sec3}
=======

As described in this section, the LIQ-GHD was developed and evaluated in a manner consistent with guidance provided by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) "Pediatric Patient-Reported Outcome Instruments for Research to Support Medical Product Labeling: Report of the ISPOR PRO Good Research Practices for the Assessment of Children and Adolescents Task Force" \[[@CR20]--[@CR22]\].

Establishing Evidence of Content Validity {#Sec4}
-----------------------------------------

'Content validity' refers to the extent to which a questionnaire measures concepts of interest in ways that are relevant and understandable to patients, comprehensive, and appropriate for the questionnaire's intended context of use \[[@CR20]\]. The target patient population for the developed questionnaire was adults (aged ≥ 25 years) as well as adolescents (aged 12--17 years) and children (aged 3--11 years). The period of 18--24 years of age is generally viewed as a 'transition period' in GHD, during which individuals with pediatric-onset GHD experience a slowed growth rate as they approach their adult height \[[@CR25]--[@CR27]\]. In order to avoid confounding the study results, and to clearly distinguish between pediatric and adult GHD populations, individuals aged 18--24 years were not included in the study population.

With this in mind, evidence for the content validity of the LIQ-GHD was developed through a targeted review of empirical literature, advice meetings with clinical experts, and qualitative interviews with adults (age ≥ 25 years) and children (age 3--17 years) taking r-hGH injections for GHD.

### Targeted Review of Empirical Literature {#Sec5}

A review of empirical literature was conducted in March 2016 using PubMed (<https://www.ncbi.nlm.nih.gov/pubmed>). Searches were conducted to identify publications with potential relevance to dosing frequency and injection issues related to hGH, and other therapeutic areas with a similar treatment regimen in adult and pediatric populations. A supplemental literature search was also conducted through review of the reference lists of publications reviewed in the original search, conference proceedings, and Google and Google Scholar. A literature-focused conceptual model \[[@CR23]\] was developed to represent r-hGH injection burden concepts and ultimately inform the selection of measurement concepts for the LIQ-GHD.

### Questionnaire Modification and Development {#Sec6}

A full-day, in-person meeting was convened by the LIQ-GHD developers, including the study sponsor, health outcomes researchers, GHD clinical experts, and COA measurement scientists. Results from the empirical literature review were reviewed and used to incorporate concepts and items from two existing questionnaires (the Injection Pen Assessment Questionnaire \[IPAQ\] \[[@CR18]\] and the Bother, Satisfaction, and Willingness to Continue \[BSW\] Questionnaire \[[@CR24]\]) and to develop new items for inclusion in the LIQ-GHD. Response scales were developed to be appropriate to the concept measured, consistent among like items, sensitive enough to capture change, and easy to use. Items assessing ease of treatment and satisfaction used a 5-point Likert-type scale to capture the entire response range from easy/satisfied to difficult/dissatisfied. Items assessing frequency of experience used a 5-point verbal response scale, while items assessing sign or symptom severity used an 11-point numeric rating scale.

### Advice Meetings with Clinical Experts {#Sec7}

One-on-one, 60-min advice meetings were conducted by telephone with clinical experts from the USA and European Union (EU). During these meetings, experts were asked to describe reported patient experiences (patients as well as caregivers) related to daily r-hGH injections and their perspective on the injection-related burdens that patients experience. Experts were also asked to provide feedback on the relevance and comprehensiveness of the draft LIQ-GHD.

### Translatability Assessment {#Sec8}

Following advice meetings with clinical experts, and before conducting qualitative patient interviews, the translatability of the draft LIQ-GHD was assessed by an independent translation provider (TransPerfect; <http://www.transperfect.com/>), in order to identify any words or terms that may pose difficulty in translation. Any wording revisions made to the LIQ-GHD during the qualitative interviews were subsequently submitted for translatability assessment.

### Qualitative Interviews with Patients and Caregivers {#Sec9}

A series of in-person, 90-min qualitative interviews were conducted with patients (and, when appropriate, their caregivers) in the USA diagnosed with GHD and receiving daily rhGH injections. Ethics approval was received from Quorum Review. Participants were recruited from four clinical sites, and included adults (aged ≥ 25 years) and adolescents (aged 12--17 years) and children (aged 3--11 years) with their caregivers. The qualitative interviews comprised two parts: (i) concept elicitation during which participants were asked open-ended questions about the r-hGH injection treatment burden and impacts they experienced due to r-hGH injections; and (ii) debriefing during which participants were asked to provide feedback on the LIQ-GHD, to assess its relevance (i.e., does it assess concepts relevant and important to participants?), comprehensiveness (i.e., does it omit any relevant concepts?), and comprehensibility (i.e., can participants understand the LIQ-GHD as intended by the developers and select meaningful responses?). Interviews were conducted in three waves to allow time for questionnaire revisions, if needed. Participant compensation was distributed upon interview completion.

### Questionnaire Revision {#Sec10}

Based on the translatability assessments and feedback from patients with GHD (and their caregivers), further updates were made to both LIQ-GHD versions: wording and organization were revised, and some concepts for measurement were added prior to quantitative testing.

Evaluation of Hypothesized Factor Structure and Score Psychometric Performance {#Sec11}
------------------------------------------------------------------------------

An online, cross-sectional observational study was conducted to evaluate the LIQ-GHD hypothesized factor structure and score psychometric performance. Participants were clinician-diagnosed adult and pediatric (child and adolescent) patients receiving daily r-hGH injections for GHD, recruited from eight endocrinology clinics. Ethical approval was provided by Quorum Review and, where applicable, local ethical review boards. Consented participants completed the LIQ-GHD online at home. Questions related to the shared injection experience were completed by child and adolescent patients together with their caregiver (dyad administration). To enable test--retest analysis, the LIQ-GHD was completed twice in the same session with a brief interval between administrations, during which time participants completed a demographic form and the Self-Injection Assessment Questionnaire (SIAQ) \[[@CR28]\]. Participant compensation was distributed upon questionnaire completion.

Analyses were conducted for the overall study sample and age-related subgroups (i.e., children, adolescents, and adults).

### Factor Structure {#Sec12}

Confirmatory factor analysis (CFA) was conducted to confirm the hypothesized factor structure of the LIQ-GHD (as summarized in Table [1](#Tab1){ref-type="table"} and presented in Fig. [1](#Fig1){ref-type="fig"}). The LIQ-GHD measures six hypothesized domains: Pen Ease of Use (PEoU; five items), Ease of Injection Schedule (EoIS; two items), Patient Life Interference (LI; five- or seven-item version), Satisfaction and Willingness to Continue Treatment (WtC; two items), Missed Injections (two items), and Injection Signs and Symptoms (SS; four items). Additional domains were hypothesized for the LIQ-GHD pediatric version: Injection Signs Reported by Caregiver (CS; two items), Caregiver Life Interference (CLI; five- or seven-item version), and Family Life Interference (FLI; five- or six-item version). CFA models were run for the overall sample and by age subgroup. Model fit was assessed with the comparative fit index (CFI) and root mean square error of approximation (RMSEA). CFI values can range between 0 and 1, with higher values indicative of better fit, and CFI \> 0.95 is considered to be a good fit. RMSEA values ranging from 0.08 to 0.10 are considered an indication of fair fit, and RMSEA values above 0.10 indicated poor fit \[[@CR29]\]. The following models were run: Model 1---overall sample (excluding CLI and FLI items which are specific to only the pediatric subgroups); Model 2---overall sample (replicating Model 1, but run with LI \[five items\]); Model 3---combined pediatric sample (including the caregiver reported CLI and FLI items); Model 4---combined pediatric sample (excluding the caregiver-reported CLI and FLI items and the CS items); and Model 5---combined pediatric sample (excluding the CLI and FLI items and the SS items).Table 1Summary description of the Life Interference Questionnaire for Growth Hormone Deficiency (LIQ-GHD)Hypothesized domainCompleted byQuestion contentResponse scalePen Ease of Use (PEoU), 5 itemsAdultDyad(Recall: past 4 weeks)Overall pen ease of useEase of use: prepare the penEase of use: set the doseEase of use: inject the medicineEase of use: store the pen5-point Likert typeEase of Injection Schedule (EoIS), 2 itemsAdultDyad(Recall: past 4 weeks)Ease of injection schedule overallConvenience of injection schedule overall5-point Likert type7-point Likert typePatient Life Interference (LI), 5 or 7 itemsAdultDyad(Recall: past 4 weeks)Interference with usual daily activitiesInterference with social activitiesInterference with recreation and leisure activitiesInterference with spending the night away from homeInterference with travel*7-item version includes these 2 additional items*Changes to life routine to deal with injectionsBothered by growth hormone injections5-point VRSSatisfaction and Willingness to Continue (WtC), 2 itemsAdultDyad(Recall: past 4 weeks)Satisfaction with overall experience taking growth hormone treatmentWillingness to continue injection schedule5-point Likert type5-point VRSMissed Injections, 2 itemsAdultDyad(Recall: past 4 weeks)Number of missed injectionsReason(s) for missing injectionsContinuousMultiple choiceInjection Signs and Symptoms (SS) (patient reported), 4 itemsAdultPediatric patient (ages 8--17 years only)(Recall: past week)Pain severityStinging severityBruising severityBleeding severity11-point NRSInjection Signs (CS) (caregiver reported), 2 itemsCaregiver of pediatric patient (all ages)(Recall: past week)Bruising severityBleeding severity11-point NRSCaregiver Life Interference (CLI), 5 or 7 itemsCaregiver of pediatric patient(Recall: past 4 weeks)Interference with caregiver usual daily activitiesInterference with caregiver social activitiesInterference with caregiver recreation and leisure activitiesInterference with caregiver spending night away from homeInterference with the caregiver travel*7-item version includes these 2 additional items*Changes to caregiver life routine to deal with child injectionsCaregiver bothered by growth hormone injections5-point VRSFamily Life Interference (FLI), 5 or 6 itemsCaregiver of pediatric patient(Recall: past 4 weeks)Interference with family member usual daily activitiesInterference with family member social activitiesInterference with family member recreation and leisure activitiesInterference with family member spending night away from homeInterference with family member travel*6-item version contains this additional item*Changes to family member life routine to deal with child injections5-point VRS*NRS* numeric rating scale, *VRS* verbal rating scaleFig. 1Hypothesized domain framework evaluated by CFA

### Psychometric Score Performance {#Sec13}

LIQ-GHD item-level frequencies and descriptives, as well as domain-level descriptives, were calculated for the overall, child, adolescent, and adult groups. Descriptive statistics included the mean, median, and range for each statistic calculated.

Item-to-item correlations were calculated for each item against the other items using Spearman's rank order correlation coefficient (rho), with rho \> 0.80 indicating potential redundancy between items.

Item-total correlations were examined between items and hypothesized domains, as well as items and other domain scores, following the multi-method multi-trait paradigm \[[@CR30]\]. Items should correlate ≥ 0.40 with domains to which they are hypothesized to belong, and demonstrate no or weak correlation with other domains \[[@CR31]\].

Internal consistency reliability was estimated using Cronbach's coefficient alpha (*α*) \[[@CR32]\], which ranges from 0 to 1, with *α* ≥ 0.70 being considered acceptable.

Intra-class correlation coefficients (ICCs) were calculated to assess test--retest reliability of the LIQ-GHD item and domain scores, using a two-way mixed model (Shrout and Fleiss ICC) \[[@CR33]\]. The ICC ranges from 0.00 to 1.00 with a minimal acceptable level of 0.70 for group comparisons \[[@CR34]\].

Construct-related validity was evaluated by generating convergent and discriminant validity correlation estimates and conducting a set of known-groups analyses.

For tests of convergent/discriminant validity, hypothesized relationships among LIQ-GHD and SIAQ variables were estimated using Spearman rho. Evidence for convergent validity was based on rho ≥ \|0.40\|, and evidence for discriminant validity was based on rho \< \|0.30\| \[[@CR30], [@CR35]\].

Known-groups-methods analyses characterize the degree to which scores produced by a target questionnaire can distinguish among the groups hypothesized a priori to be clinically distinct \[[@CR20]\]. Known groups were defined in five ways: group (i) changes to life routine in order to deal with GH injections; group (ii) number of missed injections; group (iii) satisfaction with overall experience taking GH treatment; group (iv) GHD severity; and group (v) overall health rating. These five groups were selected with the expectation that subgroup members would differ clinically and/or that they would have a higher score in the LIQ-GHD. We expected the LIQ-GHD scores to reflect the differences within these groups. Between-group differences were evaluated using the *t* test or analysis of variance, or non-parametric analyses such as the Mann--Whitney *U* test or Kruskal--Wallis test when normality assumptions were not met. For parametric analyses, standardized effect sizes (Cohen's *d*, difference in means divided by pooled standard deviation \[SD\]) were calculated to quantify the magnitude of the differences between groups and interpreted as follows: *d* = 0.2 as a small effect size, *d* = 0.5 as a medium effect size, and *d* = 0.8 as a large effect size \[[@CR36]\].

Results {#Sec14}
=======

Establishing Evidence of Content Validity {#Sec15}
-----------------------------------------

### Targeted Review of Empirical Literature {#Sec16}

A targeted search of empirical literature yielded 315 potentially relevant abstracts for review. Abstracts were screened and additional publications were identified from supplemental searches, resulting in a total of 30 publications selected for full review (see Fig. [2](#Fig2){ref-type="fig"}). Concepts emerging from the reviewed publications primarily focused on ease or difficulty of injection device use, injection regimen, injection-related adverse effects, and injection-related impacts. The identified concepts were organized into a literature-based conceptual model (see Fig. [3](#Fig3){ref-type="fig"}) and used to inform questionnaire modification and development.Fig. 2Flow chart describing the identification of publications for the empirical literature reviewFig. 3Literature-based injection burden conceptual model

### Questionnaire Modification and Development {#Sec17}

Two existing questionnaires, the IPAQ (a questionnaire measuring r-hGH device ease of use) and the BSW (a questionnaire measuring benefit from, satisfaction with, and willingness to continue treatment) were modified, and included in the draft LIQ-GHD, for this study's context of use. New questionnaire content was developed to measure concepts identified during the literature review. Table [1](#Tab1){ref-type="table"} presents a summary of the LIQ-GHD item content and response option format.

### Advice Meetings with Clinical Experts {#Sec18}

Six clinical experts in the USA (*n* = 3) and the EU (*n* = 3) took part in advice meetings. All six experts had a minimum of 9 years' experience treating individuals with GHD, and half had more than 20 years' experience. During these meetings, experts were asked about their patients' experience with r-hGH injections and how r-hGH injections impact the lives of patients and caregivers. Experts reported many of the same concepts identified in the literature (see Table [2](#Tab2){ref-type="table"}). Experts were also asked to review the draft LIQ-GHD and provide feedback. Although individual experts had suggestions for revising the LIQ-GHD, there were no consistent or fundamental issues identified that would call into question the appropriateness and comprehensiveness of the questionnaire.Table 2Patient and caregiver reported recombinant human growth hormone injection-related conceptsConceptFrequency of patient report (*N* = 21)Reported by clinical expertsIdentified in reviewed literatureIncluded in LIQ-GHDSigns and symptoms related to r-hGH injections PainTotal: 15 (71.4%)Child^a^: 9 (81.8%)Adolescent^b^: 3 (75.0%)Adult^c^: 3 (50.0%)✓✓✓ BleedingTotal: 12 (57.1%)Child: 7 (63.6%)Adolescent: 3 (75.0%)Adult: 2 (33.3%)✓✓ BruisingTotal: 11 (52.3%)Child: 7 (63.6%)Adolescent: 2 (50.0%)Adult: 2 (33.3%)✓✓✓ StingingTotal: 7 (33.3%)Child: 5 (45.5%)Adolescent: 1 (25.0%)Adult: 1 (16.7%)✓✓✓ LumpsTotal: 4 (19.0%)Child: 4 (36.4%)Adolescent: 0 (0.0%)Adult: 0 (0.0%) Mark on the skinTotal: 1 (4.8%)Child: 1 (9.1%)Adolescent: 0 (0.0%)Adult: 0 (0.0%) Cold sensationTotal: 2 (9.5%)Child: 0 (0.0%)Adolescent: 1 (25.0%)Adult: 1 (16.7%) BurningTotal: 2 (9.5%)Child: 0 (0.0%)Adolescent: 1 (25.0%)Adult: 1 (16.7%)✓ Dry skinTotal: 1 (4.8%)Child: 1 (9.1%)Adolescent: 0 (0.0%)Adult: 0 (0.0%) EdemaTotal: 1 (4.8%)Child: 1 (9.1%)Adolescent: 0 (0.0%)Adult: 0 (0.0%) ItchTotal: 1 (4.8%)Child: 1 (9.1%)Adolescent: 0 (0.0%)Adult: 0 (0.0%) Sensation of pressureTotal: 1 (4.8%)Child: 0 (0.0%)Adolescent: 1 (25.0%)Adult: 0 (0.0%) RednessTotal: 1 (4.8%)Child: 1 (9.1%)Adolescent: 0 (0.0%)Adult: 0 (0.0%) ScarringTotal: 1 (4.8%)Child: 0 (0.0%)Adolescent: 0 (0.0%)Adult: 1 (16.7%) Withdrawal symptoms^d^Total: 1 (4.8%)Child: 0 (0.0%)Adolescent: 1 (25.0%)Adult: 0 (0.0%)Impact domains related to r-hGH injections Impacts on travelTotal: 18 (85.7%)Child: 11 (100.0%)Adolescent: 3 (75.0%)Adult: 4 (66.7%)✓✓✓ Emotional impactsTotal: 15 (71.4%)Child: 9 (81.8%)Adolescent: 2 (50.0%)Adult: 4 (66.7%)✓✓✓ Limitations to overnight activitiesTotal: 9 (42.9%)Child: 7 (63.6%)Adolescent: 2 (50.0%)Adult: 0 (0.0%)✓✓ Limitations to usual daily activitiesTotal: 7 (33.3%)Child: 6 (54.5%)Adolescent: 1 (25.0%)Adult: 0 (0.0%)✓✓ Social impactsTotal: 3 (14.3%)Child: 2 (18.2%)Adolescent: 0 (0.0%)Adult: 1 (16.7%)✓✓✓ Limitations to recreational/leisure activitiesTotal: 2 (9.5%)Child: 1 (9.1%)Adolescent: 1 (25.0%)Adult: 0 (0.0%)✓ Work impactsTotal: 1 (4.8%)Child^e^: 0 (0.0%)Adolescent: 0 (0.0%)Adult: 1 (16.7%)✓✓✓ Impacts on familyTotal: 1 (4.8%)Child: 1 (9.1%)Adolescent: 0 (0.0%)Adult: 0 (0.0%)✓✓✓ Impacts on relationshipsTotal: 1 (4.8%)Child: 0 (0.0%)Adolescent: 0 (0.0%)Adult: 1 (16.7%)✓✓✓*LIQ-GHD* Life Interference Questionnaire for Growth Hormone Deficiency, *r-hGH* recombinant human growth hormone^a^Dyad interviews with 11 children aged 4--11 years, with their caregivers^b^Dyad interviews with 4 adolescents aged 12--17 years, with their caregivers^c^Interviews with 6 adults aged ≥ 25 years^d^Physical symptoms experienced by one adolescent after several days without r-hGH injections

### Questionnaire Revision {#Sec19}

Following the expert advice meetings, the LIQ-GHD was organized into two versions: the LIQ-GHD-Adult (intended for adults ≥ 25 years of age) and the LIQ-GHD-Pediatric (intended for children and adolescents 3--17 years of age and their caregivers). The LIQ-GHD-Adult is a patient self-reported outcome (PRO) measure. For most questions, the LIQ-GHD-Pediatric is a COA intended for 'dyad administration' in which the patient and caregiver read and answer questions together. LIQ-GHD-Pediatric questions asking about the severity of injection symptoms are administered only with children and adolescents capable of reliable self-report, while some observer-reported outcome (ObsRO) items are answered by the caregiver about his/her own experiences, experiences of the family, and observable behaviors of the child.

### Translatability Assessment {#Sec20}

While some minor recommendations for formatting and word choice were made to increase the translatability of the instruments across languages, the translatability assessment confirmed that the LIQ-GHD-Adult and LIQ-GHD-Pediatric could be effectively translated into a wide range of languages.

### Qualitative Interviews with Patients and Caregivers {#Sec21}

Qualitative interviews were conducted with 21 individuals with GHD (11 children \< 12 years of age and their caregivers, four adolescents 12--17 years of age and their caregivers, and six adults ≥ 25 years of age). Table [3](#Tab3){ref-type="table"} presents participant demographic and health information.Table 3Participant demographic and health informationDemographic and health informationQualitative interviews (*N* = 21)Field study (*N* = 224)Adults (*n* = 6)Pediatric (*n* = 15)Adults (*n* = 75)Adolescents (*n* = 79)Children (*n* = 70)Age Mean years (SD)47.8 (12.6)9.7 (3.4)50.3 (11.7)13.9 (1.4)8.7 (2.2) Minimum--maximum years32.0--62.04.0--15.028.0--87.012.0--17.03.0--11.0Sex \[*n* (%)\] Male4 (66.7)11 (73.3)25 (33.3)60 (75.9)44 (62.9) Female2 (33.3)4 (26.7)50 (66.7)19 (24.1)26 (37.1)Race \[*n* (%)\] Asian0 (0.0)1 (6.7)0 (0.0)4 (5.1)5 (7.1) Black or African-American0 (0.0)0 (0.0)1 (1.3)2 (2.5)2 (2.9) American Indian or Alaska Native0 (0.0)1 (6.7)0 (0.0)0 (0.0)0 (0.0) Native Hawaiian or other Pacific Islander0 (0.0)0 (0.0)0 (0.0)1 (1.3)0 (0.0) White6 (100.0)10 (66.7)71 (94.7)63 (79.7)55 (78.6) Other0 (0.0)3 (20.0)3 (4.0)9 (11.4)8 (11.4)GHD severity \[*n* (%)\] Very mild0 (0.0)1 (6.7)0 (0.0)0 (0.0)0 (0.0) Mild1 (16.7)3 (20.0)6 (8.0)7 (8.9)2 (2.9) Moderate2 (33.3)8 (53.3)29 (38.7)40 (50.6)33 (47.1) Severe1 (16.7)1 (6.7)27 (36.0)27 (34.2)28 (40.0) Very severe2 (33.3)0 (0.0)13 (17.3)5 (6.3)7 (10.0) Not answered0 (0.0)2 (13.3)0 (0.0)0 (0.0)0 (0.0)*GHD* growth hormone deficiency

Concept elicitation results confirmed that the LIQ-GHD comprehensively captures key aspects of the r-hGH injection experience (see Table [2](#Tab2){ref-type="table"} for a summary of concepts reported by patients and caregivers). All injection-related SS concepts reported by \> 25% of the total sample were included in the LIQ-GHD, as were all impact domains reported by patients and their caregivers.

Cognitive debriefing results indicated that the LIQ-GHD instructions, items, and response options were generally well-understood. While a few of the younger children had comprehension issues, the nature of the dyad administration mitigated this finding (i.e., in these instances, the caregiver read the question to the child and arrived at a response together with the child). Minor wording revisions were made following these interviews in an effort to improve patient understanding. In addition, questions were added to assess bleeding, bother caused by injections, and number of and reasons for missed injections.

Evaluation of Hypothesized Factor Structure and Score Psychometric Performance {#Sec22}
------------------------------------------------------------------------------

A total of 224 participants were included in the online observational study, including 70 children (age 3--11 years)/caregiver dyads, 79 adolescent (age 12--17 years)/caregiver dyads, and 75 adults (age ≥ 25 years). The patient sample ranged from 3 to 87 years in age. More than half of the patients were male (58%), and the majority were white (84%) (see Table [3](#Tab3){ref-type="table"}).

### Confirmatory Factor Analysis {#Sec23}

CFA using the overall sample demonstrated good-fit statistics for the hypothesized domain structure (without the family LI and caregiver LI items) using both the five- and seven-item patient LI domains (RMSEA = 0.07, CFI = 0.98 for each). CFA demonstrated good-fit statistics for both Model 1 (RMSEA = 0.07, CFI = 0.98) and Model 2 (RMSEA = 0.07, CFI = 0.98) in the overall group (with the travel and spending the night away from home \[i.e., overnight\] items correlated), supporting the hypothesized factor structure. Model 3 did not converge. CFA demonstrated good-fit statistics for Model 4 (five-item LI: RMSEA = 0.07, CFI = 0.97; seven-item LI: RMSEA = 0.08, CFI = 0.95) (with the travel and overnight items correlated). CFA demonstrated good-fit statistics for Model 5 (five-item LI: RMSEA = 0.07, CFI = 0.97; seven-item LI: RMSEA = 0.08, CFI = 0.96) (with the travel and overnight items correlated).

### Item Distributions {#Sec24}

The evaluation of item distributions for the full study sample demonstrated floor effects for most items of the LIQ-GHD, though no ceiling effects were observed for any items. For most items, all response options were used, although the upper end of the scale was not selected for some items. The findings for specific subanalyses based on patient age groups were similar to the overall sample. No missing data were observed as the electronic administration of the measure did not allow items to be skipped.

### Item-to-Item Correlations {#Sec25}

Evaluation of item-to-item correlations suggested possible redundancy between four sets of items in the LIQ-GHD: items assessing interference with spending the night away from home (i.e., overnight) and interference with travel, for patients, caregivers, and family members; items assessing interference with recreation and leisure activities and interference with social activities, for caregivers and family members; items assessing patient-reported and caregiver-reported bruising; and items assessing patient- and caregiver-reported bleeding.

### Item-Total Correlations {#Sec26}

In general, the items correlated as expected with their hypothesized domains in the overall, child, adolescent, and adult groups and, for the most part, items correlated more strongly with their hypothesized domains than with other domain scores. There were some exceptions to this; for example, while the bother item correlated well with its hypothesized seven-item LI domain, it correlated more strongly with the WtC and patient-reported symptoms (SS) domains. Item-total correlations for the WtC domain were generally moderate to weak (i.e., \< 0.40 correlation). Not unexpectedly, moderate correlations were observed for patient LI and the caregiver LI and family LI items, and for the SS and caregiver-reported sign (CS) items.

### Internal Consistency Reliability {#Sec27}

For the overall study sample, internal consistency reliability was demonstrated for all domains (with Cronbach's α ranging from 0.746 to 0.905), with two exceptions (see Table [4](#Tab4){ref-type="table"}). Similarly, all domains in all subgroups met the threshold of *α* ≥ 0.70 for internal consistency reliability, with few exceptions (see Table [4](#Tab4){ref-type="table"}).Table 4Internal consistency reliability estimates for the overall sample, and by child, adolescent, adult groupsDomainsCronbach's alpha (*α*)Overall sample (*N* = 224)Child/caregiver dyads (*n* = 70)Adolescent/caregiver dyads (*n* = 79)Adult (*n* = 75)PEoU (*k* = 5)0.7460.7580.7590.720EoIS^a^ (*k* = 2)0.8180.7740.8530.820LI (*k* = 7)0.8530.7300.8840.874LI (*k* = 5)0.8220.6510.8590.866WtC^a^ (*k* = 2)0.5890.3460.5790.788SS^b^ (*k* = 4)0.7570.8070.7060.579CS^a,c^ (*k* = 2)0.6530.5520.718CLI (*k* = 7)0.8760.8100.901CLI (*k* = 5)0.8460.7670.877FLI (*k* = 6)0.9050.8150.936FLI (*k* = 5)0.8850.7550.927*CLI* Caregiver Life Interference, *CS* injection signs reported by caregiver, *EoIS* Ease of Injection Schedule, *FLI* Family Life Interference, *LI* Life Interference, *PEoU* Pen Ease of Use, *SS* Injection Signs and Symptoms, *WtC* Satisfaction and Willingness to Continue^a^Results should be interpreted with caution as the domain score is based on only two items^b^Patient-reported, ages 8--17 years and ≥ 25 years^c^Caregiver-reported for children ages 3--17 years

### Test--Retest Reliability {#Sec28}

ICCs for the LIQ-GHD domain scores ranged from 0.761 to 0.918 for the overall sample (see Table [5](#Tab5){ref-type="table"}). Results were similar when analyzed by subgroup, with an ICC \> 0.70 being observed for most of the LIQ-GHD across age groups, with the exception of the EoIS and WtC in children (with ICC = 0.679 and ICC = 0.697, respectively).Table 5Test--retest reliability of Life Interference Questionnaire for Growth Hormone Deficiency (LIQ-GHD) domains, overall groupDomains*N*Time 1 \[mean (SD)\]Time 2 \[mean (SD)\]Reliability (ICC)95% confidence intervalLowerUpperPEoU (*k* = 5)2241.3 (0.5)1.4 (0.6)0.7610.7000.811EoIS (*k* = 2)2241.8 (1.8)1.8 (1.9)0.7680.7080.817LI (*k* = 7)2241.7 (0.7)1.7 (0.7)0.8570.8180.888LI (*k* = 5)2241.7 (0.7)1.6 (0.7)0.8540.8150.886WtC (*k* = 2)2241.6 (0.6)1.5 (0.7)0.7680.7080.817SS^a^ (*k* = 4)2051.6 (1.4)1.3 (1.4)0.9090.8820.930CS^b^ (*k* = 2)1491.0 (1.2)0.9 (1.1)0.8090.7450.858CLI (*k* = 7)1491.6 (0.7)1.6 (0.6)0.8870.8470.917CLI (*k* = 5)1491.6 (0.7)1.5 (0.7)0.8650.8180.900FLI (*k* = 6)1491.3 (0.6)1.4 (0.6)0.9180.8880.940FLI (*k* = 5)1491.3 (0.6)1.4 (0.6)0.8960.8600.924*CLI* Caregiver Life Interference, *CS* injection signs reported by caregiver, *EoIS* Ease of Injection Schedule, *FLI* Family Life Interference, *LI* Life Interference, *PEoU* Pen Ease of Use, *SS* Injection Signs and Symptoms, *WtC* Satisfaction and Willingness to Continue^a^Patient-reported, ages 8--17 years and ≥ 25 years^b^Caregiver-reported for children ages 3--17 years

### Convergent and Divergent Validity {#Sec29}

Table [6](#Tab6){ref-type="table"} presents correlations between LIQ-GHD and SIAQ domain scores for the overall group. As predicted, results demonstrated evidence of convergence between the PEoU and SIAQ Ease of use of the injection device scores, and between the WtC and SIAQ Satisfaction with self-injection scores. However, inconclusive results were found for the EoIS and SIAQ Satisfaction with self-injection scores and for the patient LI (five-item) and SIAQ satisfaction with self-injection scores. As predicted, inconclusive correlation results were found for caregiver LI (five-item) and SIAQ Feelings about injections scores, and divergence was found between family LI (five-item) and SIAQ Feelings about injection scores.Table 6Correlations between Life Interference Questionnaire for Growth Hormone Deficiency (LIQ-GHD) and Self-Injection Assessment Questionnaire (SIAQ) scores, overall sampleLIQ-GHD domainsSIAQ domain scores^a^Feelings about injectionsSelf-imageSelf-confidencePain and skin reactionEase of useSatisfactionPEoU^b^− 0.214− 0.158− 0.090− 0.388− 0.429^c^− 0.371EoIS^d^− 0.185− 0.152− 0.049− 0.245− 0.276− 0.323^e^LI (7-item)^f^− 0.403− 0.337− 0.177− 0.527− 0.415− 0.437^c^LI (5-item)^f^− 0.336− 0.294− 0.144− 0.439− 0.352− 0.368WtC^g^− 0.254− 0.232− 0.191− 0.413− 0.340− 0.474^c^SS^h,i^− 0.426− 0.338− 0.231− 0.683− 0.428− 0.402CLI (7-item)^f^− 0.435− 0.303− 0.040− 0.462− 0.342− 0.343CLI (5-item)^f^− 0.369^e^− 0.289− 0.040− 0.410− 0.283− 0.318FLI (6-item)^f^− 0.230− 0.1880.009− 0.297− 0.313− 0.258FLI (5-item)^f^− 0.225^j^− 0.198− 0.030− 0.302− 0.302− 0.282*CLI* Caregiver Life Interference, *EoIS* Ease of Injection Schedule, *FLI* Family Life Interference, *LI* Life Interference, *PEoU* Pen Ease of Use, *SS* Injection Signs and Symptoms, *WtC* Satisfaction and Willingness to Continue^a^SIAQ domain scores range from 0 to 10, with higher scores associated with better experience with self-injection^b^Adult and dyad LIQ-GHD items range from 1 to 5, with higher scores associated with greater difficulty^c^Confirmed hypothesized convergent correlation^d^Adult and dyad LIQ-GHD items range from 1 to 7, with higher scores associated with greater inconvenience^e^Hypothesized correlation undetermined^f^Adult and dyad LIQ-GHD items range from 1 to 5, with higher scores associated with more interference^g^Adult and dyad LIQ-GHD items range from 1 to 5, with higher scores associated with less satisfaction^h^Adult and dyad LIQ-GHD items range from a count over the past 4 weeks^i^Patient-reported, ages 8--17 years and ≥ 25 years^j^Confirmed hypothesized discriminant correlation

For the child group, evidence of convergence among domain scores was not found; however, evidence of divergence was found between caregiver LI (five-item) and SIAQ Feelings about injections scores and between family LI (five-item) and SIAQ Feelings about injections scores.

For the adolescent group, evidence of convergence was found for PEoU and SIAQ Ease of use of the injection device scores and for the WtC and SIAQ Satisfaction with self-injection scores, but not for other domains, as predicted; evidence of divergence was found for family LI (five-item) and SIAQ Feelings about injection scores.

For the adult group, evidence of convergence was found for all scores (PEoU and SIAQ Ease of use of the injection device, EoIS and SIAQ Satisfaction with self-injection domain, patient LI \[five-item\] and SIAQ Satisfaction with self-injection, and WtC and SIAQ Satisfaction with self-injection), as predicted.

### Known Groups {#Sec30}

For the overall sample, the LI (five-item) and EoIS domain scores differed significantly for groups reporting changes/no changes to life routine, satisfied/dissatisfied with treatment, and number of missed injections (see Table [7](#Tab7){ref-type="table"}). Specifically, participants reporting frequent changes to life routine, dissatisfaction with treatment, and higher number of missed injections had higher LI and injection schedule difficulty (see Figs. [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"} respectively). No significant differences were found based on self-rating of overall health or GHD severity level. Some similar results were observed in the child, adolescent, and adult group analyses; however, these analyses were limited due to small sample size.Table 7Known-group analysis of the LI-5 and EoIS domain scores (overall group, *N* = 224)DomainComparison group*N*Mean (SD)Median*p* ValuePost hoc tests^f^SES^g^ParametricNon-parametricChanges/no changes to life routine LI (5-item)No changes1871.5 (0.54)1.4\< 0.001^a^\< 0.001^e^2.00Changes372.6 (0.69)2.6 EoISNo changes1871.5 (1.54)0.8\< 0.001^a^\< 0.001^e^1.05Changes373.2 (2.31)2.9Missed injections LI (5-item)None (0)781.5 (0.63)1.40.056^c^0.045^d^1 vs. 20.35Few (1--3)1231.8 (0.73)1.60.21Some or many (≥ 4)^h^231.7 (0.73)1.40.14 EoISNone (0)781.1 (1.37)0.8\< 0.001^c^\< 0.001^d^1 vs. 2, 1 vs. 3, 2 vs. 30.41Few (1--3)1231.8 (1.80)1.71.46Some or many (≥ 4)^h^233.4 (2.08)2.90.87Satisfaction with overall experience taking GHD treatment LI (5-item)Satisfied1871.6 (0.64)1.4\< 0.001^a^\< 0.001^e^0.83Not satisfied372.2 (0.81)2.2 EoISSatisfied1871.5 (1.58)0.8\< 0.001^a^\< 0.001^e^1.09Not satisfied373.3 (2.11)2.9Overall health rating LI (5-item)Excellent741.7 (0.70)1.40.456^c^0.466^d^− 0.02Very good/good1341.7 (0.72)1.4− 0.35Fair/poor161.5 (0.56)1.3− 0.32 EoISExcellent741.7 (1.65)1.70.207^c^0.399^d^0.01Very good/good1341.7 (1.82)0.80.48Fair/poor162.5 (2.32)1.90.44GHD severity LI (5-item)Mild or moderate1171.7 (0.72)1.40.919^b^0.442^e^0.01Severe1071.7 (0.69)1.4 EoISMild or moderate1171.8 (1.88)0.80.602^b^0.356^e^− 0.07Severe1071.7 (1.73)0.8*EoIS* Ease of Injection Schedule, *GHD* growth hormone deficiency, *LI* Life Interference, *SD* standard deviation, *SES* standardized effect size^a^*p* Values are from a Satterthwaite *t*-test comparing distributional differences between groups^b^*p* Values are from a pooled *t*-test comparing distributional differences between groups^c^*p* Values are from an analysis of variance comparing difference between mean scores between groups^d^*p* Values are from a Kruskal--Wallis test comparing distributional differences between groups^e^*p* Values are from a Mann--Whitney *U* test comparing distributional differences between groups^f^Post hoc (Tukey) comparisons listed were significant at the 0.05 level^g^Between-group SESs were calculated as the difference between group means divided by the pooled SD^h^Respondents answering 'Some' (*n* = xx) or 'Many' (*n* = xx) on this item were combined into a single group for analysis. Statistical comparisons were presented but should be considered exploratory due to the small *n*Fig. 4Known-groups analysis: number of missed injections (key results). Higher scores represent more injection schedule interference and difficulty; for interference, *p *\< 0.05 none vs. 1--3/month, Mann--Whitney *U* test; for difficulty, *p *\< 0.0001 for all post hoc comparisonsFig. 5Known-groups analysis: satisfaction or dissatisfaction with treatment (key results). Higher scores represent more injection schedule interference and difficulty; *p* \< 0.001, Mann--Whitney *U* testFig. 6Known-groups analysis: changes to routine (key results). Higher scores represent more injection schedule interference and difficulty; *p *\< 0.001, Mann--Whitney *U* test

Discussion {#Sec31}
==========

Results from this research, conducted in accordance with best practices \[[@CR21], [@CR22], [@CR37], [@CR38]\], provide evidence of the LIQ-GHD content and construct validity and score psychometric performance, based on a targeted literature review, expert advice meetings, interviews with patients and caregivers, and data from a quantitative field study.

The literature review revealed a paucity of data relating to r-hGH injection treatment burden (the most-cited references were related to diabetes \[[@CR39]--[@CR43]\]) and identified several functional health domains (e.g., emotional, role, travel, physical function) that may be impacted by daily injection treatment.

Results from the clinical expert advice meetings confirmed the literature findings and informed development of the draft LIQ-GHD.

Qualitative patient and caregiver interviews confirmed that the most important and relevant concepts related to r-hGH injection treatment burden were included in the LIQ-GHD, that participants understood and were able to answer the questions, and that it comprehensively covers relevant concepts. Interview results also confirmed the overall feasibility of the dyad administration approach.

Results from cognitive debriefing provide evidence that the minimum age for reliable self-report on symptom questions is 8 years. Thus, the administrative instructions for the LIQ-GHD specify that symptom questions be administered only to respondents ≥ 8 years of age, and questions that assess observable signs (e.g., bleeding and bruising questions) be administered to caregivers.

Following qualitative interviews, the LIQ-GHD was finalized and tested in a cross-sectional, observational field study. Results from the field study confirmed the hypothesized factor structure of the LIQ-GHD and yielded preliminary evidence of score reliability and construct validity in measuring treatment burden of daily r-hGH injections.

As observed in the literature review, evidence suggests that the burden of daily r-hGH injections has a negative effect on treatment adherence and thus on effectiveness. While data show that pediatric and adult patients with GHD may acclimate to daily r-hGH injections, they still continue to experience associated burden and impacts \[[@CR44]\]. The availability of a less frequent injection schedule could address many of the burdens and barriers identified.

The research presented here adds to the r-hGH injection treatment burden evidence base and reinforces results from similar research undertaken by others that also identified daily injection LI, as well as emotional and social impacts \[[@CR45], [@CR46]\].

Evaluation of item frequency distributions identified a floor effect for many LIQ-GHD items, which is a possible study limitation and an important concern with regards to measurement. The floor effect was present but less notable for some questions (e.g., 'spending the night away from home' and 'travel' LI items, and the convenience question). Items with substantive floor or ceiling effects can limit the instrument's range of measurement (and thereby limit the responsiveness of the tool). One possible strategy to mitigate the potential consequences of a floor effect is to extend the lowest extreme response anchor. However, for most of these items, the lowest response category is 'Never'. One likely explanation for this finding is that most (if not all) patients in this target patient population follow a frequent (i.e., daily) r-hGh injection regimen, may have acclimated to that routine, and may not have any knowledge, exposure to, or experience with a less frequent regimen. Indeed, in this study's qualitative interviews, patients and caregivers indicated that they have made adaptations to their lives to deal with the burden of daily treatment injections. This may explain the floor effects observed on the LIQ-GHD items. While this may be the case, establishing a standardized method for the assessment of LI is important for these patients. The LIQ-GHD includes items that are written in such a manner that they may be used (or easily modified) to assess the patient experience with varied injection regimens. Future studies employing the LIQ-GHD should be powered (e.g., ensuring sufficient sample size to detect an effect or change) with these considerations in mind.

Another possible limitation is the short interval between the time 1 and time 2 LIQ-GHD administrations for the evaluation of test--retest reliability (although efforts were made for the participants to complete other questionnaires during the interval). Additionally, some of the known-groups analyses could not be completed due to the small sample size for grouping categories. Because this was primarily a cross-sectional study design, longitudinal analyses were not conducted to evaluate score interpretation. Future psychometric research should replicate these reliability and validity analyses and evaluate score interpretation.

One other possible limitation to the data is that the development and testing of this LIQ-GHD was only carried out with US patients and caregivers. However, there does not appear to be evidence (e.g., from the literature) suggesting that the burden of daily r-hGH injections may differ substantially for patients residing in other parts of the world. Future research can confirm content relevance and performance of the LIQ-GHD in countries outside of the USA.

The benefits of a less frequent injection regimen might be further explored and elucidated in future research assessing the within-person difference in experience of more frequent (e.g., daily) versus less frequent (e.g., weekly) injections.

The LIQ-GHD may be useful for capturing and assessing aspects of the injection treatment burden of individuals receiving r-hGH injections. Addressing patient preferences for treatment may improve compliance, adherence, and, ultimately, clinical outcomes \[[@CR47]--[@CR49]\].

Conclusion {#Sec32}
==========

The LIQ-GHD is a new COA tool, designed for self- or dyad-administration, that has demonstrated evidence of content validity, reliability, and construct validity. The LIQ-GHD measures concepts that are important and relevant to patients (and their caregivers) and can be used to characterize the r-hGH injection treatment burden experienced by patients (and caregivers, where appropriate), to inform patient--healthcare provider communications and optimal individualized treatment decisions that may improve treatment compliance and adherence and long-term outcomes for GHD patients. The results of this research provide evidence that the LIQ-GHD is fit for use in clinical trials including adult patients (≥ 25 years of age), adolescents (12--17 years of age), and children (3--11 years of age) to establish treatment benefit in new GHD interventions.

Components of this research were summarized in individual poster presentations, including: ISPOR 22nd Annual International Meeting, Boston, MA, USA 20--24 May 2017; ISPOR 20th Annual European Congress, Glasgow, Scotland, 4--8 November 2017; ISPOR 23rd Annual International Meeting, Baltimore, MD, USA, 19--23 May 2018; and the 57th Annual European Society for Paediatric Endocrinology (ESPE) Meeting, Athens, Greece, 27--29 September 2018.
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